A carregar...
Nonclinical and clinical pharmacology evidence for cardiovascular safety of saxagliptin
BACKGROUND: In the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR) trial in patients with type 2 diabetes mellitus (T2D) at high risk of cardiovascular (CV) disease, saxagliptin did not increase the risk for major CV adverse events. However, there was...
Na minha lista:
Publicado no: | Cardiovasc Diabetol |
---|---|
Main Authors: | , , , , , , |
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
BioMed Central
2017
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5598064/ https://ncbi.nlm.nih.gov/pubmed/28903775 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-017-0595-6 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|